BCMA Immunotherapy, Bispecific Platforms, and CD38 Antibodies in Myeloma: Optimizing Treatment and Enhancing Access


Share

Program Content

Activities

  • Immunotherapy in MM
    Immunotherapy, Bispecific Platforms, and CD38 Antibodies in Myeloma: Optimizing Treatment & Enhancing Access
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: May 17, 2024

    Expires: May 16, 2025

Faculty

cover img faculity

Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO

Cleveland Clinic Taussig Cancer Institute
Department of Hematology and Medical Oncology
Member, Population and Cancer Prevention Program
Case Comprehensive Cancer Center
Cleveland, Ohio

Supporters

Supported by an educational grant from Sanofi Genzyme.

Sanofi Genzyme